Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2

  • Authors:
    • Kuan-Der Lee
    • Hsin-Wei Chen
    • Chih-Cheng Chen
    • Yan-Chung Shih
    • Hsing-Kun Liu
    • Mei-Lien Cheng
  • View Affiliations

  • Published online on: May 1, 2006     https://doi.org/10.3892/or.15.5.1211
  • Pages: 1211-1216
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

T cells can be activated in vitro by monoclonal antibodies to CD3 (anti-CD3) to become non-MHC restricted killer cells (CD3-AK). Anti-CD3 activation upregulates the expression of the interleukin (IL)-2 receptors on T cells whose expansion is facilitated by IL-2. The therapeutic effect of in vivo administration of anti-CD3 and IL-2 has been investigated in many types of human cancers. To circumvent the toxicities posed by systemic administration of high-dose IL-2, there is interest in forming a strategy for targeting and concentrating IL-2 at the site where it is needed. This study investigates the feasibility of constructing a novel fusion protein consisting of IL-2 fused to the constant region of anti-CD3 antibody. Our results indicate that the specific IL-2 receptor-binding capability and bioactivity of the IL-2 portion as well as the CD3-binding and biological functions of anti-CD3 portion remain intact in this anti-CD3/IL-2 fusion protein. Thus, cytokines fused to anti-CD3 antibody by genetic engineering is feasible and may provide a new class of immunotherapeutics for cancer.

Related Articles

Journal Cover

May 2006
Volume 15 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lee K, Chen H, Chen C, Shih Y, Liu H and Cheng M: Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncol Rep 15: 1211-1216, 2006
APA
Lee, K., Chen, H., Chen, C., Shih, Y., Liu, H., & Cheng, M. (2006). Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncology Reports, 15, 1211-1216. https://doi.org/10.3892/or.15.5.1211
MLA
Lee, K., Chen, H., Chen, C., Shih, Y., Liu, H., Cheng, M."Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2". Oncology Reports 15.5 (2006): 1211-1216.
Chicago
Lee, K., Chen, H., Chen, C., Shih, Y., Liu, H., Cheng, M."Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2". Oncology Reports 15, no. 5 (2006): 1211-1216. https://doi.org/10.3892/or.15.5.1211